Elise Dumas, Postdoctoral Researcher at EPFL (École polytechnique fédérale de Lausanne), shared a post on LinkedIn:
“Are there differences in the effectiveness of the different aromatase inhibitors as adjuvant endocrine therapy for breast cancer?
New publication in JAMA Network Open
Outcomes of Anastrozole, Letrozole, and Exemestane in Patients With Postmenopausal Breast Cancer.
– In this study, we analyzed data from a large population-based cohort of postmenopausal patients with breast cancer (n ≈ 148,000).
– Using a target trial emulation framework, we estimated outcomes under hypothetical interventions consisting anastrozole, letrozole, or exemestane, both under natural (observed) persistence, and under a “perfect persistence” scenario.
– We also compared our estimates with findings from prior randomized clinical trials.
Main finding
Exemestane was associated with slightly lower disease-free survival and overall survival at 8 years compared with anastrozole and letrozole, under both natural and perfect persistence. These results are consistent with previous randomized trials, though earlier randomized trials were likely underpowered to detect differences of this magnitude.
Many thanks to all co-authors and collaborators across EPFL, Institute of Women’s Cancers Institut Curie, Institut national du cancer and other partner institutions.”
Title: Outcomes of Anastrozole, Letrozole, and Exemestane in Patients With Postmenopausal Breast Cancer
Authors: Elise Dumas, Anne-Sophie Hamy, Kerollos Nashat Wanis, Floriane Jochum, Florence Coussy, Sylvie Giacchetti, Thomas Gaillard, Enora Laas, Sophie Houzard, Christine Le Bihan-Benjamin, Fabien Reyal, Paul Gougis, Mats Julius Stensrud
You Can Read More about Breast Cancer on OncoDaily.